SEC Form 3 · accession 0001209191-19-002600
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keri Lantz
Officer — See Remarks
Period of report
Jan 1, 2019
Accepted (ET)
Jan 7, 2019 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 11,848 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF1 | $3.28 | holding | — | — | — | — | Dec 18, 2019 | Common Stock | 13,000 | — | D |
| Employee Stock OptionF1 | $3.10 | holding | — | — | — | — | Dec 16, 2020 | Common Stock | 25,000 | — | D |
| Employee Stock OptionF1 | $7.59 | holding | — | — | — | — | Dec 12, 2021 | Common Stock | 9,500 | — | D |
| Employee Stock OptionF1 | $8.64 | holding | — | — | — | — | Dec 18, 2022 | Common Stock | 12,900 | — | D |
| Employee Stock OptionF1 | $3.02 | holding | — | — | — | — | Dec 17, 2023 | Common Stock | 20,000 | — | D |
| Employee Stock OptionF1 | $13.80 | holding | — | — | — | — | Dec 4, 2024 | Common Stock | 14,100 | — | D |
| Employee Stock OptionF2 | $7.54 | holding | — | — | — | — | Jan 25, 2026 | Common Stock | 18,000 | — | D |
| Employee Stock OptionF3 | $8.42 | holding | — | — | — | — | Jul 25, 2026 | Common Stock | 6,000 | — | D |
| Employee Stock OptionF4 | $4.17 | holding | — | — | — | — | Jan 25, 2027 | Common Stock | 30,000 | — | D |
| Employee Stock OptionF5 | $3.20 | holding | — | — | — | — | Feb 16, 2028 | Common Stock | 75,000 | — | D |
| Employee Stock OptionF6 | $2.52 | holding | — | — | — | — | Aug 6, 2028 | Common Stock | 10,000 | — | D |
Explanation of responses
- F1This option is fully vested and exercisable.
- F2This option was granted on January 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
- F3This option was granted on July 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
- F4This option was granted on January 25, 2017 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
- F5This option was granted on February 16, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
- F6This option was granted on August 6, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
Remarks
Vice President of Finance, Corporate Controller, Interim Principal Financial Officer and Interim Principal Accounting Officer. See Exhibit 24.1, Power of Attorney